Vactosertib
As of the edition of 20 October 2026, Vactosertib is a small molecule: stopped in 2026; acts on TGFBR1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2026
- Kind
- Small molecule
- Registered trials
- 20, 6 stopped early
- Disease areas
- Cancer; Digestive system; Blood and lymph; Heart and blood vessels; Hormones; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TGFBR1 | TGF-beta receptor type-1 | P36897 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 6 | 4 | 0 | 0 |
| Phase 2 | 14 | 3 | 1 | 6 |
| All trials | 20 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| MedPacto | Lead sponsor of trials | 2014 to now |